5 Common Types of Muscular Dystrophy: From Duchenne to Myotonic

Muscular dystrophy is not a single disease – it is an umbrella term for more than 30 genetic disorders that cause progressive muscle weakness and degeneration. Each type differs in which muscles are affected first, when symptoms appear, how quickly the condition worsens, and what complications it brings. For educators, caregivers, and students studying disability, understanding these differences is essential. This post breaks down five of the most significant types: Duchenne, Becker, Congenital, Facioscapulohumeral, and Myotonic Muscular Dystrophy.

What all types of muscular dystrophy have in common 🔗

Before looking at each type individually, it helps to understand the shared foundation. All muscular dystrophies are caused by genetic mutations that impair proteins essential to muscle health, leading to the progressive breakdown of muscle fibers. Over time, healthy muscle tissue is replaced by fat and scar tissue, reducing the muscles’ ability to generate force. While some types appear at birth, others do not surface until adulthood. Some shorten life expectancy significantly; others do not. The specific type matters enormously for prognosis, treatment planning, and daily support needs.

Duchenne muscular dystrophy (DMD) 🔗

Duchenne muscular dystrophy (DMD) is the most common and most severe form of the condition. It occurs almost exclusively in males because it follows an X-linked recessive inheritance pattern – the mutated gene sits on the X chromosome, and since boys have only one X chromosome, a single faulty copy is enough to cause the disease.

The role of dystrophin 🔗

At the heart of DMD is the absence of a protein called dystrophin. Dystrophin acts as a kind of shock absorber within muscle cells, connecting the inner scaffolding of the cell to its outer membrane and protecting fibers from the mechanical stress of repeated contractions. When dystrophin is absent, muscle cells sustain damage with every movement, triggering a destructive cycle of degeneration, inflammation, and eventual replacement by fibrous tissue and fat.

Symptoms and progression 🔗

DMD most commonly appears between ages 3 and 6, when parents begin to notice a child struggling to walk, climb stairs, or rise from the floor. A characteristic sign, known as Gowers’ sign, involves the child using their hands to push off their own legs to stand up – a compensatory maneuver for weak hip and thigh muscles. The disease typically progresses to loss of mobility by the second decade of life, and cardiac and orthopedic complications are common.

Beyond the muscles, DMD also affects the heart and lungs. Both the Duchenne and Becker forms are associated with cardiomyopathy – a condition that weakens the cardiac muscle and can develop into dilated cardiomyopathy, causing irregular heartbeat, extreme fatigue, and swelling of the limbs.

Life expectancy 🔗

A 2021 analysis found a median life expectancy of 28.1 years for people with DMD born in 1990 or later – a figure that has been steadily improving with advances in cardiac and respiratory care. The Muscular Dystrophy Association notes that with improved care, people with DMD are more commonly living into their 30s. Gene therapies and exon-skipping treatments are among the newer approaches showing promise in clinical trials.

Becker muscular dystrophy (BMD) 🔗

Becker muscular dystrophy (BMD) is caused by mutations in the same gene as DMD, but with a critical difference. Mutations that lead to a version of dystrophin that retains some function typically cause Becker, while mutations that prevent any functional dystrophin from being produced tend to cause Duchenne. That partial functionality makes BMD considerably milder in its course.

How BMD differs from DMD 🔗

BMD has similar symptoms to DMD but progresses more slowly, and complications like scoliosis and heart disease are not as common. Symptoms typically emerge in the teenage years or early adulthood, and some individuals are not diagnosed until their 20s or even 60s. Some people with BMD can have close to a normal life expectancy if they do not develop severe cardiomyopathy, though those with significant heart problems have an average lifespan of around 47 years. Mobility difficulties do occur, but wheelchair use is not inevitable for all.

Congenital muscular dystrophy (CMD) 🔗

Congenital muscular dystrophy (CMD) refers to a broad group of muscular dystrophies where symptoms are present at birth or appear before the age of two. Children with congenital muscular dystrophy may develop joint problems, scoliosis, respiratory and swallowing difficulties, seizures, or vision problems, and the central nervous system may also be affected.

What makes CMD distinct 🔗

CMD encompasses more than 30 subtypes, and the experience varies widely from child to child. Symptoms include general muscle weakness evident at birth or in infancy, along with joint deformities and possible cognitive issues. Some subtypes are associated with brain malformations. The prognosis is typically poor for severely affected patients, who are often wheelchair dependent by age 12. However, milder cases do exist – some individuals reach adulthood with only minor disabilities. The range of outcomes depends on the specific genetic subtype and the organs involved.

Facioscapulohumeral muscular dystrophy (FSHD) 🔗

Facioscapulohumeral muscular dystrophy (FSHD) takes its name directly from the parts of the body it most affects: the face (facio), shoulder blades (scapulo), and upper arms (humeral). It is the third most common type of muscular dystrophy, with an estimated prevalence of about 4 cases per 100,000 individuals.

Symptoms and onset 🔗

Symptoms usually develop during the teenage years, with most people noticing problems by age 20, although weakness in some muscles can begin as early as infancy or as late as the 50s. Facial weakness is commonly the first sign – people with FSHD often cannot purse their lips to whistle, struggle to drink through a straw, or sleep with their eyes slightly open because they cannot fully close them. Weakness in the muscles that hold the shoulder blades in place causes them to protrude when the arms are raised – a feature called scapular winging.

As the disease progresses, weakness can spread to the abdomen, hips, and lower legs. Around half of all FSHD patients also experience subclinical high-frequency hearing loss and abnormalities in the blood vessels at the back of the eye. Around 20 percent will need a wheelchair by age 50, and over 70 percent experience debilitating pain and fatigue.

Prognosis 🔗

FSHD is most typically characterized by relatively slow disease progression, and life expectancy is not shortened. There is currently no cure, but physical therapy, orthotic devices, and in some cases surgical scapular fixation can help maintain function and manage pain.

Myotonic muscular dystrophy 🔗

Myotonic muscular dystrophy is the most common form of adult-onset muscular dystrophy. It is caused by mutations in the DMPK gene (type 1) or the CNBP gene (type 2) and affects males and females equally. Unlike the other types discussed here, myotonic dystrophy is inherited in a dominant pattern – only one copy of the mutated gene from one parent is sufficient to cause the condition.

The defining feature: myotonia 🔗

What sets this type apart is myotonia – the inability of muscles to relax after contraction. With myotonic dystrophy, the muscles cannot relax at will; for example, it may be hard to let go of someone’s hand after shaking it. Facial and neck muscles are often the first to be affected, and symptoms often begin between the ages of 20 and 30, though some experience them from childhood.

Systemic complications 🔗

Myotonic dystrophy extends well beyond the muscles. It can cause cataracts, gastrointestinal problems such as constipation and diarrhea, endocrine disturbances including thyroid issues and diabetes, and difficulty with muscle relaxation in the hands and wrists. As the disease progresses, it can cause abnormal heart rhythm or a weakened heartbeat – in severe cases, some individuals require a pacemaker or cardiac defibrillator.

Type 2 myotonic dystrophy is generally milder than type 1, and among people with type 1, earlier onset forms are more aggressive than adult-onset forms. Treatment remains focused on symptom management, including medications to address the myotonia, cardiac monitoring, and respiratory support as needed.

A quick comparison at a glance 🔗

Each of these five types has a distinct genetic origin, age of onset, and clinical profile. DMD is the most severe and the earliest to appear, while BMD shares its genetic roots but follows a milder course. CMD is unique in being present at or near birth and carries the highest risk of developmental and neurological complications. FSHD targets the upper body in a characteristic asymmetric pattern and typically spares life expectancy. Myotonic dystrophy, the most common adult form, introduces the unusual problem of muscle stiffness alongside weakness, and affects multiple organ systems beyond muscle tissue alone.

Understanding these distinctions is not just academic. For educators and support professionals working with individuals with muscular dystrophy, knowing which type a person has – and what to expect at different stages – shapes how educational environments, physical supports, and communication strategies are designed. Accurate identification of the specific type is a key part of diagnosis, because it informs treatment approach and long-term outlook.

What do you think? How might a classroom or educational setting need to adapt differently for a student with early-onset Duchenne muscular dystrophy compared to one diagnosed with Facioscapulohumeral muscular dystrophy in their teens? And as treatments for conditions like DMD continue to advance, how should educators stay informed about the evolving needs of students living with progressive conditions?

References

1. https://www.cdc.gov/muscular-dystrophy/types/index.html
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC5788182/
3. https://www.mda.org/disease/duchenne-muscular-dystrophy
4. https://medlineplus.gov/genetics/condition/duchenne-and-becker-muscular-dystrophy/
5. https://www.duchenne.com/understanding-duchenne/about-duchenne
6. https://www.hopkinsmedicine.org/health/conditions-and-diseases/duchenne-muscular-dystrophy
7. https://www.ncbi.nlm.nih.gov/books/NBK482346/
8. https://www.healthline.com/health/life-expectancy-duchenne-muscular-dystrophy
9. https://www.mymdteam.com/resources/what-is-the-life-expectancy-with-duchenne-muscular-dystrophy
10. https://musculardystrophynews.com/muscular-dystrophy-types/
11. https://www.mymdteam.com/resources/types-of-muscular-dystrophy-duchenne-becker-and-more
12. https://nyulangone.org/conditions/muscular-dystrophy/types
13. https://www.mda.org/disease/facioscapulohumeral-muscular-dystrophy
14. https://www.mda.org/disease/facioscapulohumeral-muscular-dystrophy/signs-and-symptoms
15. https://my.clevelandclinic.org/health/diseases/facioscapulohumeral-muscular-dystrophy-fshd
16. https://www.ncbi.nlm.nih.gov/books/NBK559028/
17. https://www.fshdsociety.org/living-with-fshd/understanding-fshd/
18. https://rarediseases.org/rare-diseases/facioscapulohumeral-muscular-dystrophy/
19. https://www.mayoclinic.org/diseases-conditions/muscular-dystrophy/symptoms-causes/syc-20375388